Literature DB >> 10891962

Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity.

J Stamler1, M L Daviglus, D B Garside, A R Dyer, P Greenland, J D Neaton.   

Abstract

CONTEXT: Based on observational and interventional data for middle-aged cohorts (aged 40-64 years), serum cholesterol level is known to be an established major risk factor for coronary heart disease (CHD). However, findings for younger people are limited, and the value of detecting and treating hypercholesterolemia in younger adults is debated.
OBJECTIVE: To evaluate the long-term impact of unfavorable serum cholesterol levels on risk of death from CHD, cardiovascular disease (CVD), and all causes. DESIGN, SETTING, AND PARTICIPANTS: Three prospective studies, from which were selected 3 cohorts of younger men with baseline serum cholesterol level measurements and no history of diabetes mellitus or myocardial infarction. A total of 11,017 men aged 18 through 39 years screened in 1967-1973 for the Chicago Heart Association Detection Project in Industry (CHA); 1266 men aged 25 through 39 years examined in 1959-1963 in the Peoples Gas Company Study (PG); and 69,205 men aged 35 through 39 years screened in 1973-1975 for the Multiple Risk Factor Intervention Trial (MRFIT). MAIN OUTCOME MEASURES: Cause-specific mortality during 25 (CHA), 34 (PG), and 16 (MRFIT) years of follow-up; mortality risks; and estimated life expectancy in relation to baseline serum cholesterol levels.
RESULTS: Death due to CHD accounted for 26%, 34%, and 28% of all deaths in the CHA, PG, and MRFIT cohorts, respectively; and CVD death for 34%, 42%, and 39% of deaths in the same cohorts, respectively. Men in all 3 cohorts with unfavorable serum cholesterol levels (200-239 mg/dL [5.17-6.18 mmol/L] and >/=240 mg/dL [>/=6.21 mmol/L]) had strong gradients of relative mortality risk. For men with serum cholesterol levels of 240 mg/dL or greater (>/=6.21 mmol/L) vs favorable levels (<200 mg/dL [<5.17 mmol/L]), CHD mortality risk was 2.15 to 3.63 times greater; CVD disease mortality risk was 2.10 to 2.87 times greater; and all-cause mortality was 1.31 to 1.49 times greater. Hypercholesterolemic men had age-adjusted absolute risk of CHD death of 59 per 1000 men in 25 years (CHA cohort), 90 per 1000 men in 34 years (PG cohort), and 15 per 1000 men in 16 years (MRFIT cohort). Absolute excess risk was 43.6 per 1000 men (CHA), 81.4 per 1000 men (PG), and 12.1 per 1000 men (MRFIT). Men with favorable baseline serum cholesterol levels had an estimated greater life expectancy of 3.8 to 8.7 years.
CONCLUSIONS: These results demonstrate a continuous, graded relationship of serum cholesterol level to long-term risk of CHD, CVD, and all-cause mortality, substantial absolute risk and absolute excess risk of CHD and CVD death for younger men with elevated serum cholesterol levels, and longer estimated life expectancy for younger men with favorable serum cholesterol levels. JAMA. 2000;284:311-318

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10891962     DOI: 10.1001/jama.284.3.311

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  148 in total

1.  Around PediHeart: hyperlipidemia.

Authors:  F McCaffrey
Journal:  Pediatr Cardiol       Date:  2001 Jan-Feb       Impact factor: 1.655

Review 2.  Monogenic dyslipidemias: window on determinants of plasma lipoprotein metabolism.

Authors:  R A Hegele
Journal:  Am J Hum Genet       Date:  2001-10-26       Impact factor: 11.025

3.  Racial and ethnic disparity in blood pressure and cholesterol measurement.

Authors:  Scott H Stewart; Marc D Silverstein
Journal:  J Gen Intern Med       Date:  2002-06       Impact factor: 5.128

Review 4.  If suicide is a public health problem, what are we doing to prevent it?

Authors:  Kerry L Knox; Yeates Conwell; Eric D Caine
Journal:  Am J Public Health       Date:  2004-01       Impact factor: 9.308

5.  Ideal cardiovascular health and mortality from all causes and diseases of the circulatory system among adults in the United States.

Authors:  Earl S Ford; Kurt J Greenlund; Yuling Hong
Journal:  Circulation       Date:  2012-01-30       Impact factor: 29.690

Review 6.  Framingham-based tools to calculate the global risk of coronary heart disease: a systematic review of tools for clinicians.

Authors:  Stacey Sheridan; Michael Pignone; Cynthia Mulrow
Journal:  J Gen Intern Med       Date:  2003-12       Impact factor: 5.128

7.  Association of Cardiovascular Risk Factors With MRI Indices of Cerebrovascular Structure and Function and White Matter Hyperintensities in Young Adults.

Authors:  Wilby Williamson; Adam J Lewandowski; Nils D Forkert; Ludovica Griffanti; Thomas W Okell; Jill Betts; Henry Boardman; Timo Siepmann; David McKean; Odaro Huckstep; Jane M Francis; Stefan Neubauer; Renzo Phellan; Mark Jenkinson; Aiden Doherty; Helen Dawes; Eleni Frangou; Christina Malamateniou; Charlie Foster; Paul Leeson
Journal:  JAMA       Date:  2018-08-21       Impact factor: 56.272

Review 8.  The role of early LDL lowering to prevent the onset of atherosclerotic disease.

Authors:  Brian A Ference; Nitin Mahajan
Journal:  Curr Atheroscler Rep       Date:  2013-04       Impact factor: 5.113

9.  Associations Between the Serum Metabolome and All-Cause Mortality Among African Americans in the Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  Bing Yu; Gerardo Heiss; Danny Alexander; Morgan E Grams; Eric Boerwinkle
Journal:  Am J Epidemiol       Date:  2016-03-07       Impact factor: 4.897

10.  Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin.

Authors:  Susan G Lakoski; Fang Xu; Gloria L Vega; Scott M Grundy; Manisha Chandalia; Chun Lam; Robert S Lowe; Michael E Stepanavage; Thomas A Musliner; Jonathan C Cohen; Helen H Hobbs
Journal:  J Clin Endocrinol Metab       Date:  2009-12-04       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.